Robert Bessler Sells 894,337 Shares of LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 894,337 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $10.13, for a total transaction of $9,059,633.81. Following the completion of the sale, the director owned 539,763 shares in the company, valued at $5,467,799.19. This represents a 62.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Robert Bessler also recently made the following trade(s):

• On Tuesday, May 12th, Robert Bessler sold 575,034 shares of LifeStance Health Group stock. The stock was sold at an average price of $8.02, for a total transaction of $4,611,772.68.
• On Thursday, May 7th, Robert Bessler sold 75,000 shares of LifeStance Health Group stock. The stock was sold at an average price of $8.55, for a total transaction of $641,250.00.
• On Friday, April 24th, Robert Bessler sold 62,147 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.05, for a total value of $438,136.35.
• On Thursday, April 23rd, Robert Bessler sold 7,752 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total value of $54,264.00.
• On Tuesday, April 21st, Robert Bessler sold 5,101 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.01, for a total value of $35,758.01.

LifeStance Health Group Stock Up 6.7%

LifeStance Health Group stock opened at $11.43 on Thursday. LifeStance Health Group, Inc. has a 1-year low of $3.74 and a 1-year high of $11.48. The business has a fifty day moving average price of $8.15 and a 200-day moving average price of $7.34. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.48 and a quick ratio of 1.48. The stock has a market capitalization of $4.43 billion, a price-to-earnings ratio of 190.50 and a beta of 1.12.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. The company had revenue of $403.48 million during the quarter, compared to analysts’ expectations of $387.46 million. LifeStance Health Group had a return on equity of 1.56% and a net margin of 1.55%.The firm’s revenue for the quarter was up 21.2% on a year-over-year basis. Equities research analysts forecast that LifeStance Health Group, Inc. will post 0.12 EPS for the current fiscal year.

Hedge Funds Weigh In On LifeStance Health Group

A number of institutional investors have recently bought and sold shares of the business. Assetmark Inc. boosted its holdings in shares of LifeStance Health Group by 17.0% in the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock valued at $60,000 after acquiring an additional 1,367 shares during the last quarter. Park Edge Advisors LLC raised its holdings in shares of LifeStance Health Group by 14.4% during the fourth quarter. Park Edge Advisors LLC now owns 11,863 shares of the company’s stock worth $84,000 after purchasing an additional 1,495 shares during the last quarter. California State Teachers Retirement System raised its holdings in shares of LifeStance Health Group by 1.6% during the fourth quarter. California State Teachers Retirement System now owns 125,682 shares of the company’s stock worth $885,000 after purchasing an additional 1,966 shares during the last quarter. Vident Advisory LLC lifted its position in LifeStance Health Group by 12.7% during the second quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock valued at $112,000 after purchasing an additional 2,447 shares during the period. Finally, Xponance LLC lifted its position in LifeStance Health Group by 26.4% during the fourth quarter. Xponance LLC now owns 13,144 shares of the company’s stock valued at $93,000 after purchasing an additional 2,745 shares during the period. 85.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on LFST. Jefferies Financial Group raised shares of LifeStance Health Group to a “strong-buy” rating in a report on Thursday, March 12th. BTIG Research upped their target price on LifeStance Health Group from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Zacks Research upgraded LifeStance Health Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 27th. The Goldman Sachs Group assumed coverage on LifeStance Health Group in a research note on Friday, June 5th. They issued a “neutral” rating and a $9.00 target price for the company. Finally, Wall Street Zen cut LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 13th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.75.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.